Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer

Published:2020-07-22 Issue:18 Volume:9 Page:6463-6472
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Toppmeyer Deborah L.¹^ORCID,Press Michael F.²

Affiliation:

1. Department of Medicine Robert Wood Johnson Medical SchoolRutgers Cancer Institute of New Jersey New Brunswick NJ USA

2. Department of Pathology Keck School of Medicine University of Southern California Los Angeles CA USA

Funder

Novartis Pharmaceuticals Corporation

Breast Cancer Research Foundation

Tower Cancer Research Foundation

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3278

Reference55 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States

3. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significance of phosphoinositide 3-kinase inhibitors in advanced breast cancer: a systematic review and meta-analysis;Clinical and Translational Oncology;2024-08-10

2. PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories;Pharmacogenomics;2024-02

3. Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy;Cancers;2023-01-23

4. PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative;Journal of Personalized Medicine;2022-10-31

5. 1,2,3-Triazole Derivatives with Anti-breast Cancer Potential;Current Topics in Medicinal Chemistry;2022-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3